PMID- 33354917
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20220531
IS  - 1467-789X (Electronic)
IS  - 1467-7881 (Linking)
VI  - 22
IP  - 6
DP  - 2021 Jun
TI  - GLP-1 agonists for obesity and type 2 diabetes in children: Systematic review and 
      meta-analysis.
PG  - e13177
LID - 10.1111/obr.13177 [doi]
AB  - Pharmacological options for management of obesity and type 2 diabetes mellitus 
      (T2DM) in children are limited. We aimed to synthesize published randomized 
      controlled trial (RCT) evidence on the efficacy of glucagon-like peptide-1 
      (GLP-1) agonists in T2DM, pre-diabetes, and obesity in children aged <18 years. 
      Inclusion criteria were RCTs of any GLP-1 agonist, solely or in conjunction with 
      other drugs, for the treatment of obesity, pre-diabetes, and/or T2DM in children 
      aged <18 years old. Nine studies met the inclusion criteria (two for T2DM, one 
      for pre-diabetes, and six for obesity without diabetes). In total, 286 children 
      were allocated to GLP-1 agonist therapy. Compared with controls, GLP-1 agonist 
      therapy reduced HbA1c by -0.30% (95% confidence interval [CI] -0.57, -0.04) with 
      a larger effect in children with (pre-)diabetes (-0.72%; 95% CI -1.17, -0.28; 
      three studies) than in children with obesity (-0.08%; 95% CI -0.13, -0.02; four 
      studies). Conversely, GLP-1 agonist therapy reduced body weight more in children 
      with obesity (-2.74 kg; 95% CI -3.77, -1.70; six studies) than in children with 
      T2DM (-0.97 kg; 95% CI -2.01, 0.08; two studies). Adverse effects included 
      gastrointestinal symptoms and minor hypoglycemic episodes, but not severe 
      hypoglycemia. GLP-1 agonists are efficacious in treating children with obesity 
      and/or T2DM. Effect sizes are comparable with those reported in adults.
CI  - (c) 2020 World Obesity Federation.
FAU - Chadda, Karan R
AU  - Chadda KR
AUID- ORCID: 0000-0002-8060-8408
AD  - Department of Paediatrics, University of Cambridge, Cambridge, UK.
FAU - Cheng, Tuck Seng
AU  - Cheng TS
AUID- ORCID: 0000-0003-4442-7332
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, 
      Cambridge, UK.
FAU - Ong, Ken K
AU  - Ong KK
AD  - Department of Paediatrics, University of Cambridge, Cambridge, UK.
AD  - MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, 
      Cambridge, UK.
LA  - eng
GR  - MC_UU_00006/2/MRC_/Medical Research Council/United Kingdom
GR  - MC_UU_12015/2/MRC_/Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20201222
PL  - England
TA  - Obes Rev
JT  - Obesity reviews : an official journal of the International Association for the 
      Study of Obesity
JID - 100897395
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptide 1/antagonists & inhibitors
MH  - Glucagon-Like Peptide-1 Receptor
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - *Pediatric Obesity/drug therapy
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - glucagon-like peptide-1
OT  - obesity
OT  - pediatric
OT  - type 2 diabetes
EDAT- 2020/12/24 06:00
MHDA- 2021/10/16 06:00
CRDT- 2020/12/23 05:54
PHST- 2020/11/05 00:00 [revised]
PHST- 2020/09/12 00:00 [received]
PHST- 2020/11/12 00:00 [accepted]
PHST- 2020/12/24 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2020/12/23 05:54 [entrez]
AID - 10.1111/obr.13177 [doi]
PST - ppublish
SO  - Obes Rev. 2021 Jun;22(6):e13177. doi: 10.1111/obr.13177. Epub 2020 Dec 22.